Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May 13;106(6):e2393-e2401.
doi: 10.1210/clinem/dgab130.

The Role for Metyrosine in the Treatment of Patients With Pheochromocytoma and Paraganglioma

Lucinda M Gruber  1 , Sina Jasim  2 , Allison Ducharme-Smith  3 , Toby Weingarten  4 , William F Young  1 , Irina Bancos  1
Affiliations

The Role for Metyrosine in the Treatment of Patients With Pheochromocytoma and Paraganglioma

Lucinda M Gruber et al. J Clin Endocrinol Metab. .

Abstract

Context: Treatment of pheochromocytoma and paraganglioma (PPGL) requires preintervention titration of alpha- and beta-adrenergic blockade, but patients may still be at risk for complications from catecholamine excess. Metyrosine decreases catecholamine production, making it an attractive therapeutic adjunct for select patients.

Evidence acquisition: A systematic literature review was performed (Ovid Medline and Scopus databases) on December 17, 2019, including studies with humans and original data. Studies with 10 or more patients on metyrosine for PPGL were included. Studies were screened for overlapping populations, and the most comprehensive study was included. The references of included studies were reviewed for additional data. Patient data from our institution between 2000 and 2015 were also reviewed.

Evidence synthesis: Metyrosine is well tolerated when used for a short course and can improve intraoperative outcomes in PPGL. Metyrosine should be considered when a difficult PPGL resection is expected (eg, pericardiac paraganglioma, abdominal paraganglioma with great vessel involvement), a large release of catecholamines is anticipated (eg, ablative therapy, chemotherapy), or when standard alpha- and beta-adrenergic blockade are not tolerated or cannot adequately control hypertension. Side effects are generally mild and self-limited, with sedation in a majority of patients. Extrapyramidal side effects are rare but can limit use of metyrosine. Because of its expense and limited availability, metyrosine use should be carefully planned and timed in relation to surgery.

Conclusions: Metyrosine is a safe addition to traditional alpha- and beta-adrenergic blockade and should be considered in those patients with PPGL at high risk for acute release of catecholamines.

Keywords: metyrosine; paraganglioma; pheochromocytoma; side effect; surgery; tyrosine hydroxylase inhibitor.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Metyrosine inhibits tyrosine hydroxylase, the rate-limiting step in catecholamine synthesis.
Figure 2.
Figure 2.
Timing of preoperative and pre-procedure medications for paraganglioma and pheochromocytoma.
Figure 3.
Figure 3.
Summary of metyrosine side effects across studies.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Mayo C. Paroxysmal hypertension with tumor of retroperitoneal nerve: report of case. JAMA. 1928;89:1047-1050.
    1. Bai S, Yao Z, Zhu X, et al. . Risk factors for postoperative severe morbidity after pheochromocytoma surgery: a single center retrospective analysis of 262 patients. Int J Surg. 2018;60:188-193. - PubMed
    1. Prejbisz A, Lenders JW, Eisenhofer G, Januszewicz A. Mortality associated with phaeochromocytoma. Horm Metab Res. 2013;45(2):154-158. - PubMed
    1. Hamidi O, Young WF Jr, Gruber L, et al. . Outcomes of patients with metastatic phaeochromocytoma and paraganglioma: a systematic review and meta-analysis. Clin Endocrinol (Oxf). 2017;87(5):440-450. - PMC - PubMed
    1. Hamidi O, Young WF Jr, Iñiguez-Ariza NM, et al. . Malignant pheochromocytoma and paraganglioma: 272 patients over 55 years. J Clin Endocrinol Metab. 2017;102(9):3296-3305. - PMC - PubMed

Publication types

MeSH terms

Substances

-